Loratadine 10 mg showed no clear difference in adverse events leading to withdrawal: intermediate‐term duration of… compared with mizolastine 10 mg (low certainty).
Loratadine 10 mg showed no clear difference in adverse events leading to withdrawal: intermediate‐term duration of… compared with emedastine 2 mg (moderate certainty).
Hydroxyzine 25 mg showed no clear difference in adverse events leading to withdrawal: intermediate‐term duration of… compared with placebo (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether serlopitant 0.25 mg changes adverse events compared with placebo (very low certainty).
It is very uncertain whether serlopitant 5 mg changes adverse events compared with placebo (very low certainty).
It is very uncertain whether serlopitant 1 mg changes adverse events compared with placebo (very low certainty).
Minoxidil 2% showed no clear difference in adverse events compared with minoxidil 5% (low certainty).
Finasteride showed no clear difference in adverse events compared with placebo (low certainty).
Minoxidil showed no clear difference in adverse events compared with placebo (low certainty).
It is very uncertain whether tonsillectomy changes proportion of participants with adverse events and severe adverse… compared with no intervention (very low certainty).
It is very uncertain whether chemical peeling changes participant‐assessed adverse events (short‐term) N of participants… compared with combined chemical peeling plus any active intervention (very low certainty).
Oral hydroxychloroquine showed no clear difference in adverse events: minor compared with placebo (moderate certainty).
Oral dehydroepiandrosterone probably leads to higher adverse events: minor compared with placebo (moderate certainty).